Abstract
GnRH (LRF) agonists effectively suppress gonadotropin and sex steroid production and have become the treatment of choice for young children who have rapidly progressive, true (central) precocious puberty. Although several reports have indicated that predicted adult height improves during GnRH agonist therapy, the limited reliability and accuracy of adult height prediction methods necessitate collection of final height measurements to determine whether final height is improved. We propose to test the hypothesis that GnRH agonist therapy improves the final height of children with true precocious puberty. Final height data will be obtained from selected pediatric endocrinologists around the world. Data from patients will be included: 1) if they have achieved 98 percent or more of their final height (bone age ≥ 14 years for girls or ≥16 years for boys); 2) if they have no other condition that might alter growth potential; and 3) if compliance and effectiveness of therapy have been felt to be good. Final heights will be compared with: 1) target heights; 2) untreated and treated (progestational agents) historical controls; and 3) predicted adult heights at initiation and completion of therapy. Data regarding length of therapy, the specific drug and route of administration, complications, and length/degree of post treatment suppression will also be sought.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kelch, R., Kletter, G. FINAL HEIGHT OF CHILDREN WITH TRUE PRECOCIOUS PUBERTY TREATED WITH GnRH (LRF) AGONISTS. Pediatr Res 33 (Suppl 5), S11 (1993). https://doi.org/10.1203/00006450-199305001-00047
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00047